Skip to content
Open access

Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.

Aug 2026 · European Heart Journal · 0 citations
Medicine

TL;DR

Beyond arterial lipid deposition, TRL and Lp(a) converge on inflammatory and vascular remodeling pathways that, under the assumptions of observational mediation analysis, may explain their excess per-particle atherogenicity compared with LDL.

Abstract

Background

AND

Aims

All apolipoprotein B-containing lipoproteins are established causal factors for coronary artery disease (CAD). This study aimed to identify robust proteomic signatures of low-density lipoprotein (LDL), triglyceride-rich lipoproteins (TRL), and lipoprotein(a) [Lp(a)] and to evaluate whether these signatures illuminate biological processes underlying differences in per-particle atherogenicity.

Methods

Plasma proteins associated with LDL, TRL, and Lp(a) concentrations were identified using multivariable-adjusted regression across 2918 proteins in a primary prevention cohort based on UK Biobank (n=35,269), and findings were corroborated using one-sample Mendelian randomization. Proteins consistently identified by both approaches were summarized into lipoprotein-specific multi-protein scores and associated with incident CAD (n=1599 events) using Cox regression. High-dimensional mediation analysis quantified the proportion of lipoprotein-associated CAD risk explained by proteomic alterations. Findings were replicated in the Multi-Ethnic Study of Atherosclerosis (n=5915).

Results

Requiring concordance between observational and Mendelian randomization analyses (both Bonferroni-adjusted P<0.05), 30 proteins were identified as associated with LDL, 471 with TRL, and 53 with Lp(a). The TRL and Lp(a) signatures were distinct from the LDL signature yet overlapped substantially with each other (36 shared proteins), with common enrichment in inflammatory pathways. After adjustment for potential confounders and measured lipoprotein concentrations, the multi-protein scores for TRL (hazard ratio per 1-SD [HRSD], 1.16; 95% confidence interval [95%CI]: 1.08-1.24) and Lp(a) (HRSD, 1.09; 95%CI: 1.03-1.15), but not LDL (HRSD, 0.95; 95%CI: 0.89-1.02), were associated with incident CAD. Mediation analysis was consistent with immune activation and vascular remodeling markers mediating TRL-associated CAD risk (proportion mediated, 62%) and, in part, Lp(a)-associated risk (14%).

Conclusions

Beyond arterial lipid deposition, TRL and Lp(a) converge on inflammatory and vascular remodeling pathways that, under the assumptions of observational mediation analysis, may explain their excess per-particle atherogenicity compared with LDL.

Read PDF

Similar papers

Open access Aug 2026

Circulating lipids, lipoproteins, and the risk of idiopathic pulmonary fibrosis: a cohort study and genetic analysis

Triangulating evidence across approaches, Mendelian randomization analyses supported inverse associations of genetically predicted total cholesteryl esters and sphingomyelins with IPF risk, and highlights cholesterol and sphingolipid metabolism as potential contributors to IPF susceptibility.

Jiahao Zhu, Yu-Hao Shen, Zhe-An Yan et al. · 0 citations
Review Open access Sep 2026

Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers

Apolipoprotein B (ApoB) serves as the structural backbone of triglyceride (TG)-rich lipoproteins and low-density lipoprotein (LDL) particles and plays a key role in lipid transport. A growing body of evidence indicates that circulating ApoB levels are closely associated with the development of cardiovascular diseases s...

Ling-Ling Li, Yi-Xuan Feng, Xiao-Ya Li et al. · 0 citations
Open access Aug 2026

Causal Effects of Lipoproteins and Lipids on Atrial Fibrillation: A Mendelian Randomization Study.

Genetically predicted elevated low-density lipoprotein (LDL) cholesterol, LDL free cholesterol, LDL phospholipids, and LDL total lipids measured by NMR were associated with an increased risk of atrial fibrillation, and LDL is identified as a critical lipoprotein for predicting and treating AF.

Shuo Liu, Qi Zhang, Thida Sok et al. · 0 citations
Review Aug 2026

Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.

Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran).

José Pablo Miramontes González · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.